



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Service
Prior Authorization Criteria

CGRP Receptor Antagonists

Aimovig® (erenumab-aooe)
Emgality™ (galcanezumab-gnlm)
Ajovy™ (fremanezumab-vfrm)

Effective 11/16/2018

Prior Authorization Request Form

AIMOVIG, EMGALITY and AJOVY are calcitonin gene-related peptide receptor antagonists indicated for the preventive treatment of migraine in adults.

Prior authorization requests for may be approved if the following criteria are met:

1. The patient is within the age range as recommended by the FDA label; **AND**
2. Prescriber is a specialist or has consulted a specialist such as neurologist; **AND**
3. Patient is experiencing at least 4 migraine days per month requiring acute pharmacological management; **AND**
4. Patient has failed to achieve therapeutic goals after using one agent from each of the following classes of preventative medications (unless contraindicated):
 1. Beta Blockers (e.g. metoprolol, propranolol, timolol)
 2. Antidepressants (e.g. amitriptyline, venlafaxine)
 3. Anticonvulsants (e.g. valproate, topiramate)

Agents may be used alone or in combination, but records must indicate that the patient was compliant on each of the agents for at least 90 consecutive days (unless a documented intolerance occurred).

Initial prior authorization approval will be for 3 months. Additional therapy may be approved only with clinical documentation showing a 50% reduction in either the number of headache days per month or the overall symptom severity (as measured by MIDAS or HIT-6) compared to baseline.

References

- 1.) Aimovig Package Insert (5/2018)
- 2.) Emgality Package Insert (9/2018)
- 3.) Ajovy Package Insert (9/2018)
- 4.) UpToDate (Chronic Migraine) – Aug 10, 2018
- 5.) LexiComp monograph on Aimovig (reviewed 8/22/2018)
- 6.) ICER Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventative Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value (April 11, 2018)
- 7.) American Academy of Neurology 2012 Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults